Editorial: B cell depletion in Graves' disease: The right answer to the wrong question?

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 5, 2007, Pages 1620-1622

  Smith, Terry J ^a,b  

^a UCLA MEDICAL CENTER   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; RITUXIMAB; STEROID; THIAMAZOLE; ANTITHYROID AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

B CELL LYMPHOMA; B LYMPHOCYTE; CELL CYCLE; CELL PROLIFERATION; DERMATOMYOSITIS; DRUG WITHDRAWAL; EDITORIAL; ENDOCRINE OPHTHALMOPATHY; GIANT CELL ARTERITIS; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; IMMUNITY; IMMUNOCOMPETENT CELL; LYMPHOID TISSUE; NONHODGKIN LYMPHOMA; PLASMA CELL; PRIORITY JOURNAL; PROTEIN BINDING; RHEUMATOID ARTHRITIS; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; LYMPHOCYTE DEPLETION; NOTE; PHYSIOLOGY;

ANTIBODIES, MONOCLONAL; ANTITHYROID AGENTS; B-LYMPHOCYTES; GRAVES DISEASE; GRAVES OPHTHALMOPATHY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE DEPLETION; METHIMAZOLE;

EID: 34249855174     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-0463     Document Type: Editorial

References (20)

1. Serreze DV, Silveira PA 2003 The role of B lymphocytes as key antigen-presenting cells in the development of T cell-mediated autoimmune type 1 diabetes. Curr Dir Autoimmun 6:212-227
2. Youinou P, Jamin C, Pers JO, Berthou C, Saraux A, Renaudineau Y 2005 B lymphocytes are required for development and treatment of autoimmune diseases. Ann NY Acad Sci 1050:19-33
3. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T 2004 Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572-2581
4. Sacchi S, Federico M, Dastoli G, Fiorani C, Vinci G, Clo V, Casolari B 2001 Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab. Crit Rev Oncol Hematol 37:13-25
5. Dorner T 2006 Crossroads of B cell activation in autoimmunity: rationale of targeting B cells. J Rheumatol 33(Suppl 77):3-11
6. Martinez-Gamboa L, Brezinschek HP, Burmester GR, Dorner T 2006 Immunopathologic role of B lymphocytes in rheumatoid arthritis: rationale of B cell-directed therapy. Autoimmun Rev 5:437-442
7. Tedder TF, Engel P 1994 CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 15:450-454
8. Weetman AP 2000 Graves' disease. N Engl J Med 343:1236-1248
9. Kazim M, Goldberg RA, Smith TJ 2002 Insights into the pathogenesis of thyroid associated orbitopathy: evolving rationale for therapy. Arch Ophthalmol 120:380-386
10. Vassart G, Dumont JE 1992 The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocr Rev 13:596-611
11. Pritchard J, Horst N, Cruikshank W, Smith TJ 2002 Igs from patients with Graves' disease induce the expression of T cell chemoattractants in their fibroblasts. J Immunol 168:942-950
12. Pritchard J, Han R, Horst N, Cruikshank WW, Smith TJ 2003 Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the IGF-1 receptor pathway. J Immunol 170:6348-6354
13. Gianoukakis AG, Douglas RS, King CS, Cruikshank WW, Smith TJ 2006 Immunoglobulin G from patients with Graves' disease induces interleukin-16 and RANTES expression in cultured human thyrocytes: a putative mechanism for T-cell infiltration of the thyroid in autoimmune disease. Endocrinology 147:1941-1949
14. Douglas RS, Gianoukakis AG, Kamat S, Smith, TJ 2007 Aberrant expression of the IGF-1 receptor by T cells from patients with Graves' disease may carry functional consequences for disease pathogenesis. J Immunol 178:3281-3287
15. Salvi M, Vannucchi G, Campi I, Rossi S, Bonara P, Sbrozzi F, Guastella C, Avignone S, Pirola G, Ratiglia R, Beck-Peccoz P 2006 Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur J Endocrinol 154:511-517
16. Salvi M, Vannucchi G, Campi I, Curro N, Dazzi D, Simonetta S, Bonara P, Rossi S, Sina C, Guastella C, Ratiglia R, Beck-Peccoz P 2007 Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 156:33-40
17. El Fassi D, Nielsen CH, Bonnema SJ, Hasselbalch HC, Hegedüs L 2007 B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study. J Clin Endocrinol Metab 92:1769-1772
18. El Fassi D, Nielsen CH, Hasselbalch HC, Hegedus L 2006 Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid 16:709-710
19. Prummel MF, Terwee CB, Gerding MN, Baldeschi L, Mourits MP, Blank L, Dekker FW, Wiersinga WM 2004 A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy. J Clin Endocrinol Metab 89:15-20
20. Bartalena L, Marcocci C, Tanda ML, Piantanida E, Lai A, Marino M, Pinchera A 2005 An update on medical management of Graves' ophthalmopathy. J Endocrinol Invest 28:469-478